Enrolling By InvitationNCT06954025

High-Intensity Inpatient MDMA-Assisted Psychotherapy for PTSD

Medication studyAges 18+Netherlands

The study in practice

Understand this study

Listed age limits: from 18 years.

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateStarted: May 16, 2025

Recruitment status: Enrolling By Invitation
Enrollment listed in the registry: 20
Sponsor: ARQ National Psychotrauma Centre
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 2
Locations: Netherlands
Age range: Over 18 Years
Official registry ID: NCT06954025
Official title: Show the full official title
High-Intensity Inpatient MDMA-Assisted Psychotherapy for Treatment-Refractory Posttraumatic Stress Disorder: An Open-Label Pilot Study

Leave your email and we’ll get in touch to discuss your questions and possible next steps.

By invitation

Oegstgeest

A listed location does not confirm current availability.

FAQ

Who is behind this study?

The study sponsor is ARQ National Psychotrauma Centre.

Does this study involve medication?

Yes. The study involves medication, including High-intensity inpatient MDMA-assisted psychotherapy.

Who can participate?

Listed age limits: from 18 years.

Is this study still recruiting?

The registry lists this study as enrolling by invitation.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.